Elanco Animal Health (NYSE:ELAN) PT Lowered to $19.00

Elanco Animal Health (NYSE:ELAN) had its price objective cut by investment analysts at Barclays from $22.00 to $19.00 in a research note issued to investors on Monday, Benzinga reports. The firm currently has an “overweight” rating on the stock. Barclays‘s price target suggests a potential upside of 51.64% from the stock’s previous close.

Other equities analysts have also recently issued research reports about the stock. Piper Sandler decreased their price target on shares of Elanco Animal Health from $19.00 to $16.00 and set a “neutral” rating for the company in a research report on Monday, July 1st. Morgan Stanley lowered Elanco Animal Health from an “overweight” rating to an “equal weight” rating and decreased their target price for the company from $17.00 to $15.00 in a report on Thursday, September 19th. Finally, Stifel Nicolaus restated a “buy” rating and set a $20.00 price target on shares of Elanco Animal Health in a report on Thursday, September 19th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat.com, Elanco Animal Health has a consensus rating of “Hold” and a consensus price target of $17.00.

Elanco Animal Health Trading Up 0.2 %

Shares of NYSE ELAN opened at $12.53 on Monday. The company has a current ratio of 2.93, a quick ratio of 1.75 and a debt-to-equity ratio of 0.92. The stock has a market capitalization of $6.19 billion, a PE ratio of -4.73, a PEG ratio of 1.32 and a beta of 1.40. Elanco Animal Health has a twelve month low of $8.59 and a twelve month high of $18.80. The stock has a fifty day simple moving average of $14.23 and a 200-day simple moving average of $14.76.

Elanco Animal Health (NYSE:ELAN) last released its earnings results on Thursday, August 8th. The company reported $0.30 earnings per share for the quarter, beating the consensus estimate of $0.24 by $0.06. The company had revenue of $1.18 billion during the quarter, compared to the consensus estimate of $1.15 billion. Elanco Animal Health had a positive return on equity of 7.29% and a negative net margin of 27.94%. Elanco Animal Health’s revenue was up 12.0% compared to the same quarter last year. During the same period in the previous year, the company posted $0.18 EPS. On average, equities analysts forecast that Elanco Animal Health will post 0.91 earnings per share for the current year.

Insider Buying and Selling at Elanco Animal Health

In other Elanco Animal Health news, Director Michael J. Harrington acquired 3,500 shares of the stock in a transaction dated Thursday, August 22nd. The stock was acquired at an average cost of $14.85 per share, with a total value of $51,975.00. Following the transaction, the director now owns 81,094 shares in the company, valued at $1,204,245.90. The trade was a 0.00 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, Director Michael J. Harrington acquired 3,500 shares of Elanco Animal Health stock in a transaction dated Thursday, August 22nd. The stock was acquired at an average price of $14.85 per share, for a total transaction of $51,975.00. Following the transaction, the director now owns 81,094 shares of the company’s stock, valued at $1,204,245.90. This represents a 0.00 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Jeffrey N. Simmons bought 100,000 shares of the stock in a transaction dated Monday, August 12th. The stock was bought at an average price of $13.01 per share, with a total value of $1,301,000.00. Following the acquisition, the chief executive officer now owns 145,000 shares in the company, valued at approximately $1,886,450. This represents a 200.00 % increase in their position. The disclosure for this purchase can be found here. 0.57% of the stock is owned by insiders.

Institutional Trading of Elanco Animal Health

A number of hedge funds and other institutional investors have recently made changes to their positions in ELAN. Hedeker Wealth LLC grew its stake in Elanco Animal Health by 6.4% during the 1st quarter. Hedeker Wealth LLC now owns 82,652 shares of the company’s stock worth $1,346,000 after buying an additional 4,995 shares during the last quarter. Maryland State Retirement & Pension System raised its position in Elanco Animal Health by 10.8% in the 1st quarter. Maryland State Retirement & Pension System now owns 38,435 shares of the company’s stock valued at $626,000 after purchasing an additional 3,759 shares during the last quarter. Principal Financial Group Inc. boosted its stake in Elanco Animal Health by 55.0% during the 1st quarter. Principal Financial Group Inc. now owns 139,543 shares of the company’s stock worth $2,272,000 after purchasing an additional 49,497 shares during the period. Mirae Asset Global Investments Co. Ltd. purchased a new position in Elanco Animal Health during the 1st quarter worth $1,226,000. Finally, Janney Montgomery Scott LLC increased its stake in Elanco Animal Health by 4.3% in the first quarter. Janney Montgomery Scott LLC now owns 63,978 shares of the company’s stock valued at $1,042,000 after purchasing an additional 2,659 shares during the period. Institutional investors and hedge funds own 97.48% of the company’s stock.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.